GlassScriptPhysician profile
Gregg G Marella
NPI 1922116326
$3,470.86
in general payments reported to CMS, 2019-2025
28 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $434 · 2021: $590 · 2022: $663 · 2023: $423 · 2024: $597 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $5.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.70 |
| Education | $5.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $716.41 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $656.49 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $427.92 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Kowa Pharmaceuticals America, INC. | $292.86 | 2019-2023 | Seglentis, Livalo |
| Abbvie INC. | $255.99 | 2020-2023 | |
| Novo Nordisk INC | $230.92 | 2019-2024 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $144.62 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $103.88 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Arbor Pharmaceuticals, INC. | $89.40 | 2019-2021 | |
| Pfizer INC. | $84.08 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $65.91 | 2020-2022 | |
| Exact Sciences Corporation | $47.06 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $46.78 | 2019-2020 | |
| Eisai INC. | $39.65 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.06 | 2024 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.09 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.08 | 2025 | Voquezna |
| Allergan, INC. | $26.17 | 2020 | |
| Aytu Biopharma, INC. | $23.80 | 2019-2020 | |
| Ibsa Pharma INC. | $19.77 | 2023 | Tirosint, Licart |
| Cumberland Pharmaceuticals, INC. | $15.77 | 2024 | Kristalose |
| Sanofi Pasteur INC. | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.85 | 2020 | |
| Althera Pharmaceuticals LLC | $13.40 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.39 | 2024 | Edarbi |
| Merck Sharp & Dohme LLC | $12.33 | 2019 | |
| Acadia Pharmaceuticals INC | $12.18 | 2019 | |
| Astellas Pharma US INC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Marella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.